Translate trial design into participant experience

Start with arms and interventions

An arm is a group of participants assigned to a defined intervention or strategy. Read every arm description and match it to the intervention details. A study may compare an investigational drug with placebo, standard care, another active treatment, different doses, or a behavioral program.

Ask what each group receives, which procedures all groups share, and which tasks belong to one group. Ask whether participants can switch groups and what happens if the assigned intervention becomes unsuitable.

Read allocation and the assignment ratio

Randomization uses chance to assign participants. It helps create comparable groups and reduce selection bias. Ask for the ratio: 1:1 gives equal assignment probability across two arms; 2:1 directs twice as many assignments to one arm. More complex trials can change ratios across cohorts or stages.

Allocation concealment protects the assignment process before enrollment. It differs from masking, which controls who knows the assignment afterward. Ask when assignment occurs and whether any pre-randomization run-in period must be completed first.

Identify who is masked and how safety unblinding works

Open-label means assignment is known. Single, double, triple, and quadruple masking labels can vary by registry convention; read the named roles, such as participant, care provider, investigator, and outcomes assessor. Masking can reduce bias, yet it may change communication, medication packaging, and access to assignment information.

Ask who can unblind the assignment for a medical reason, how quickly that can happen, and who receives the information. Do not assume routine symptoms reveal the assigned group.

Understand placebo and active comparators

A placebo is designed to resemble an intervention without its active component. Some placebo-controlled trials add the study intervention or placebo to standard care. Others compare against no intervention or use a placebo where no proven therapy exists. Read the consent language for what care continues and what care changes.

An active comparator uses another treatment or strategy. Ask whether doses and schedules match usual care, whether rescue treatment is available, and what happens after worsening symptoms. NIH participant guidance (opens in a new tab) explains that volunteers may receive a control intervention and may not know their assignment until the study ends.

Map parallel, crossover, factorial, and sequential models

• Parallel: each participant stays in one assigned group.
• Crossover: each participant receives more than one intervention across periods, often separated by washout.
• Factorial: participants receive combinations that allow more than one research question to be studied.
• Sequential: assignment or enrollment can change across planned stages.
• Single-group: every participant receives the same intervention or assessment plan.

For crossover studies, mark period length, washout, carryover risk, and the total timeline. For factorial studies, list every combination you could receive.

Read outcomes and time frames

A primary outcome is the prespecified measurement central to the main research question. Secondary and exploratory outcomes examine additional questions. Read the measurement and the time frame together. A brief intervention can produce months or years of follow-up.

Ask which outcome activities require your participation, which use existing records, and whether individual findings are returned. An endpoint measures the study question; it does not promise that an intervention will help you.

Ask how cohorts and extensions affect you

Early-phase studies may enroll cohorts in sequence, test several dose levels, use sentinel dosing, or add expansion cohorts. Ask which cohort is open, which dose or procedure it uses, what prior cohorts have completed, and what safety review occurs before the next group.

An open-label extension may offer continued access after a controlled period. Ask who qualifies, what remains experimental, how long access lasts, what costs apply, and what happens when the extension ends.